(AMRN)—GSK would benefit from the FDA’s decision to grant NCE status to Vascepa, thereby precluding competition from generic Vascepa. It follows that GSK’s response to the CP in question can be construed as self-serving verbiage rather than an indication of interest in Vascepa per se or in acquiring AMRN.
I don’t know the precise prevalence of dry-eye syndrome, but it must be large insofar as Restasis is the world’s largest-selling ophthalmic drug that is not a biologic.
Market Data 
Markets 
AI
